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Comparison of SVS and ESVS carotid disease
management guidelines
William C. Mackey, MD, Christos Liapis, MD, Piergiorio Cao, MD, and Bruce Perler, MD, Boston, Mass;
Athens, Greece; Perugia, Italy; and Baltimore, MdBoth the Society for Vascular Surgery (SVS) and the
European Society for Vascular Surgery (ESVS) have now
published clinical practice guidelines for the management of
carotid artery atherosclerosis.1,2 Although the documents dif-
fer slightly in the methods used and in the level of detail, they
reveal trans-Atlantic consensus in most key areas.
The SVS document uses the grade system, which rates
strength of recommendations (I  strong and II  weak)
separately from the quality of the data on which these
recommendations are based (high, moderate, low, and very
low). In this system, recommendations are based not just
on data but also on prevailing values and preferences.3
The ESVS document uses a simpler system in which only
the quality of the supporting data are graded (A supported
by at least one high-quality randomized controlled trial
[RCT]; B  supported by good clinical trials but no RCTs;
and C supported only by expert opinion or experience).
Despite this fundamental methodologic difference, the
guidelines that emerge are quite similar (Table). First, in
symptomatic patients there is consensus that carotid end-
arterectomy (CEA) is most appropriate for patients with
carotid territory transient ischemic attack or minor stroke
with good recovery and50% (North American Symptom-
atic Carotid Endarterectomy Trial [NASCET] criteria) ip-
silateral stenosis (SVS: grade I/high; ESVS: grade A). The
ESVS document adds a guideline that CEA in symptomatic
patients should take place within 2 weeks of the symptom
(ESVS: grade A), based on an analysis of pooled data from
European Carotid Surgery Trial (ECST) and NASCET.4
There is equally strong consensus that CEA is inappro-
priate for symptomatic patients with 50% stenosis (SVS:
grade I/high; ESVS: grade A). There is general consensus
as well on the role of carotid artery stenting (CAS) in
symptomatic carotid stenosis. The SVS and the ESVS doc-
uments both support consideration of CAS in high-risk
symptomatic patients, although the recommendation and
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much weaker than those supporting CEA. The ESVS doc-
ument adds a recommendation that CEA is the preferred
treatment in symptomatic patients (ESVS: grade A) and
that midterm stroke prevention with CEA and CAS are
equivalent (ESVS: grade A), based on midterm results of
the Stent-Supported Percutaneous Angioplasty of the Ca-
rotid Artery versus Endarterectomy (SPACE) and Endar-
terectomy Versus Angioplasty in Patients With Symptom-
atic Severe Carotid Stenosis (EVA-3S) trials.5,6
In the recommendations for the management of asymp-
tomatic patients, there are some subtle differences between
the SVS and ESVS documents. The threshold degree of
stenosis for intervention in asymptomatic patients in the SVS
document is 60%, based on the Asymptomatic Carotid Ath-
erosclerosis Study (ACAS), whereas in the ESVS document, it
is 70%, based on the Asymptomatic Carotid Surgery Trial
(ACST). The SVS and ESVS documents recommend CEA for
asymptomatic patients with stenoses exceeding these thresh-
old values (SVS: grade I/high; ESVS: grade A).
Recommendations in both documents, however, in-
clude caveats: in SVS, “as long as perioperative risk is low”;
and in ESVS, “males 75 if risk 3% and younger, fit
women.” Results from the available RCTs indicate that the
ESVS gender-related caveat seems appropriate, although
data of lower quality suggest no gender-related differences
in risk or stroke prevention benefit. The ESVS age-related
caveat is more problematic because few data are available to
support an absolute age threshold over which benefit is lost.
The SVS and ESVS guidelines on the role of CAS in
asymptomatic patients reflect the considerable uncertainty
and controversy shrouding this area. The SVS document
does not support CAS for asymptomatic patients (grade
I/low). The ESVS supports CAS in asymptomatic patients
only as part of an RCT or in high-volume centers with
documented excellent results (grade C). In reality, as stated in
their discussion, the SVS authors could not reach consensus
on this recommendation, which might more properly be
grade II/low. The caveat added by the ESVS writing group is
most appropriate: “The assumption that a patient can be
treated with CAS when he has an (evidence-based) indication
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asymptomatics) has not been validated.”
The differences between the two documents are pri-
marily in their scope. The ESVS authors chose to include
much more detail on the techniques of CEA and CAS. In
general, their technical recommendations for CEA are vague
and support surgeon preference, including eversion vs longi-
tudinal technique, general vs regional anesthetic, cerebral
monitoring and protection, and completion quality control
studies. It should be noted, however, that these vague recom-
mendations are based on meta-analyses from the Cochrane
Library, reflecting the best currently available data. A more
definitive recommendation is made for carotid closure, where
patch closure is recommended over primary closure (grade A).
Also, routine shunting is not supported (grade A), but the
origin of this recommendation is unclear because the authors
present no data suggesting that routine shunting is inferior to
selective shunting or nonshunting.
The SVS writing group felt that the quality of the data
and the likely strength of recommendations with respect to
the technical aspects of CEA and CAS were such that
inclusion of only brief technical notes was appropriate. The
SVS writing group espoused a broad range of technical
options, especially for CEA, and consensus was elusive.
The ESVS writing group also included a detailed analysis
of technique for carotid stenting. The only grade A recom-
mendation to come from this analysis was for the use of dual
antiplatelet therapy (aspirin plus clopidogrel) for the peripro-
cedural period. Other technical recommendations, including
the development of validated training programs, the use of
cerebral protection devices, and the duration of dual antiplate-
let therapy, were given grade B or C.
The SVS writing group did not attempt a systematic
review of the evidence supporting technical aspects of CAS,
although the brief technical notes and recommendations from
the SVS group are nearly identical to those of the ESVS group.
Finally, the ESVS group evaluated evidence on the man-
Table. Comparison between SVS and ESVS guidelines fo
Guideline SVS
Indication for surgery in
symptomatic stenoses
50%
Timing . . .
Indication for stenting in
symptomatic stenoses
High-risk patients
Comments . . .
Indication for surgery in
asymptomatic stenoses
60%
Caveats As long as peri-op risk
Indication for stenting in
asymptomatic stenoses
Not indicated
Caveats . . .
Technical recommendations for CEA . . .
. . .
. . .
Technical recommendations for CAS . . .
CAS, Carotid artery stenting; CEA, carotid endarterectomy; ESVS, Europea
Vascular Surgery.agement of concurrent carotid disease and peripheral arterialdisease (PAD) and on the management of concurrent carotid
disease and coronary disease. Only grade C recommendations
for not deferring PAD treatment in the setting of asymptom-
atic carotid disease and for individualizing the management of
concurrent carotid and coronary disease resulted.
Comparison of the SVS and ESVS carotid disease man-
agement guidelines reveals trans-Atlantic consensus re-
garding the role of CEA in the management of symptom-
atic and asymptomatic patients. This should not be
surprising, because the relevant data are both high quality
and explicit in their clinical application. Less clear and much
less explicit are the data supporting CAS, especially in
asymptomatic patients. It is not surprising, therefore, that
the emerging role of CAS is, as of now, much less clearly
defined in both North America and Europe.
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